High-dose methotrexate (HDMTX) 
Only 20 years ago, this disease was fatal within 6 months of diagnosis in more than 80% of cases and within 2 years almost all patients died. With the modern multimodal therapy including improved supportive care 70%-80% patients have attained remission lasting more than ve years and many of them are cured. 3 Survival in acute lymphoblastic leukemia (ALL) has improved in recent decades due to recognition of the biologic heterogeneity of ALL, utilization of risk-adapted therapy and development of protocols that include optimized chemotherapy combinations, e ective central nervous system (CNS) prophylaxis, post-induction intensi cation of therapy and a prolonged maintenance phase of treatment. 4 High-dose methotrexate (HDMTX) therapy with long-term intrathecal injection has been generally accepted as an e ective regimen for the prevention of central nervous system involvement in children with acute lymphoblastic leukemia (ALL) because similar results can be obtained in preventing central nervous system leukemia as radiotherapy with relatively lower adverse e ects. 5, 6, 7 e anti folates (e.g. Methotrexate) produce the rst striking remission in leukemia and produce fast cure of a solid tumor choriocarcinoma. 8 Higher systemic doses have contributed to improved control of testicular and medullary disease. 9 For cancer, methotrexate allosterically inhibits dihydrofolate reductase (DHFR), an enzyme that participates in the tetrahydrofolate synthesis 10 thereby, inhibits DNA, RNA, and protein synthesis. It has a greater toxic e ect on rapidly dividing cells (gastrointestinal or oral mucosa malignant and myeloid cells) which replicate their DNA more frequently and thus inhibits the growth and proliferation of these noncancerous cells. 11 It can be taken orally or administered by injection (intramuscular, intravenous, subcutaneous, or intrathecal).
Myelosupression is the most common side e ect due to cytotoxic chemotherapy including MTX therapy in children with ALL. 1, 12, 13 Fever in acute leukemia is generally due to infections. Patients with neutropenia secondary to chemotherapy induced marrow failure are at great risk of overwhelming bacterial infection especially Gram positive skin ora including Staphylococcus Albus, Staphylococcus Aureus and staphylococcus Epidermidis & Gram negative bowel organisms including E coli, Protease, klebseilla and Pseudomonas. 3 Empirical antibiotic therapy should be administrated promptly to all neutropenic patients at the onset of fever. 14 Infection generally occur when absolute neutrophil count (ANC) is <500/cmm and those with ANC <100/mm3 are at greater risk. Prolong and severe neutropenia increases risk of fungal infections. 15, 16 Bacterial and fungal infections are major causes of morbidity & mortality in children during chemotherapy for ALL. Infections increase the risk of death and may also increase the risk of relapse due to interruption of treatment and need for a decrease in the dose of chemotherapeutic agent. 17 Nosocomial infections are important clinical complication as it can cause considerable morbidity and mortality; thus increase hospital stay and healthcare cost. Monitoring nosocomial infection rate is of great importance to establish preventing measures. 18 Commonly used regimens for childhood ALL in our centre include high-dose methotrexate, where, the problem of HDMTX associated infection is frequently faced. It prolongs the hospital stay, delays the chemotherapy and causes more economic burden on patients. In our limited resource and limited hospital seats and other facilities, it imparts a negative impact on treatment of other children as well. Surprisingly, published data about the incidence and characteristics of infectious complications in patients undergoing HDMTX therapy for ALL are limited. e results of this prospective observational study will help to improve supportive care strategies in patients undergoing therapy for ALL to decrease morbidity and mortality and thus to improve overall survival.
Methods
is was a prospective observational study performed in the inpatient ward of the department of Pediatrics Hemato-oncology, BSMMU to identify the incidence, common site, course, severity and main pathogens of infection during HDMTX therapy from January 2012 to June 2012 over a period of six month. Fifty children with a age range of 1-15 yrs who were diagnosed as ALL and scheduled to receive HDMTX with Leucoverin rescue at the Department of Pediatric Hematology and Oncology, BSMMU during the study period were enrolled in this study prospectively. Patients with ALL under treatment who already had fever or other signs of infections were excluded.
Baseline investigations were done prior to administration of MTX therapy. Prehydration and posthydration was done with 3 Lit/m 2 i/v saline over 24 hours before and after giving MTX. Total dose of MTX was 2.5gm/m 2 in B cell leukemia and 5gm/m 2 in T cell leukemia; given over a period of 24 hours. 10% of total MTX was given in 1 st hour and rest was given over 23 hours. Leucoverine rescue therapy was started after 42 hours of starting MTX at the dose of 15 mg/m 2 /dose every 6 hourly total 6 doses. After enrolment, detailed history and physical examination was recorded in a pre-designed questionnaire. Complete blood count with di erential count was done in the department of Pediatric Hemato-oncology. Blood culture and sensitivity and were done in the department of Microbiology of the same hospital. Blood culture was done by conventional method with 3 ml of venous blood drawn with strict asepsis in a sterile culture bottle. Follow up was done in daily basis starting from the day of infusion up to recovery or discharge from the hospital. Reports of all the relevant investigations were recorded in the questionnaire. Empirical antibiotic was started if infection was suspected (mostly 4 th generation cephalosporin in addition to aminoglycosides) & changed subsequently according to culture sensitivity. Each infectious episode was correlated to the degree of neutropenia at its onset.
e patients were classi ed as having very severe, moderate or no neutropenia when ANC was less than 100/mm 3 (very severe), 100-500/mm 3 (severe), 500-1000/mm 3 (moderate), >1000/mm 3 (no neutropenia).
If patient showed partial improvement or failure, modi cation of treatment was done by adding ceftipime and vancomycin in majority of episodes. Carbapenem with aminoglycoside were also given in few episodes. Amphotericin B was also given to few patients on clinical suspicion. After collection data was statistically analysed by using SPSS-16.
HDMTX was de ned, in this study, when the dose of MTX was 2.5gm/m 2 body surface area in B cell leukemia and 5gm/m 2 in Tcell leukemia. Any patient having fever requiring antibiotic therapy; and/or any patient having clinical signs and symptoms of infection associated with isolation of a pathogen, or any patient having an identi able site of infection by physical examination or imaging study was considered as having infection.
Results
A total of 50 patients of 1 year to 15 years of either sex were studied during the period. Among them maximum number (31, 62%) were found in the age group 1-5 years, 11(22%) belonged to 6-10 years and 8(16%) belonged to 11-15 years. Mean weight of patient was 19.09±8.69kg with a range from 9-45kg. Regarding sex distribution, 32 (64%) were male and 18 (36%) were female. Male female ratio was 1.77:1. (Table-I (Figure-1 ).
Figure-1: Outcome of the infected patients (n=19)
Recovery without modificatin Recovery with modification Death About half 10(52.6%) of the infected children received treatment for 7 to 10 days, 4(21.1%) received 8-14 days, 2(10.5%) received 15-21 days and 3 (15.8%) of the infected children received treatment for >21 days. e mean (±SD) duration of treatment received was 12.05±7.18 days with a range from 7-28 days. (Figure-2 is study showed very severe thrombocytopenia (<5000/mm 3 ) in 4 episodes (21.1%), severe thrombocytopenia (5000-10000/mm 3 ) in 4 (21.1%), moderate thrombocytopenia (10000-150000/ mm 3 ) in 1 (5.3%) and no thrombocytopenia (>150000/mm 3 ) in 10(52.6%) episodes. Twenty nine (58%) patients had total leukocyte count 4000-11000, 16 (32%) patients had total leukocyte count <4000 and rest 5 (10%) patients had total leukocyte count >11000/mm 3 . (Table -VI) . 
Figure-2: Duration of antibiotic received during infectious episodes(n=19)

Discussion
Leukemia is the most common form of childhood malignancy having a high mortality rate due to disease process as well as due to chemotherapy induced complication. A retrospective study was done by Joseph VS, Elizabeth H and Warren J 19 to nd out the cause of death among the patients who died during course of intensive combination chemotherapy including MTX. ey found the proximate cause of death was infection (24 of 26 children in complete remission) and Pneumocystis carinii pneumonia was the primary cause of death. Where as bacterial infection was the primary cause of death during marrow remission reported by Nies et el 20 , Jacques N and Judith MC 21 had done another retrospective study showing similar result. Children younger than 5 years had a higher risk of infection in this study. Here death due to infection occurred in 8% patients. Respiratory tract infections, both lower and upper, were the most common. Septicaemia was mostly due to gram negative agents. In 8.5% patients there was no obvious clinical cause of infection and microbiological investigations were negative.
Xu Weiqun et al 22 carried out a retrospective study in order to observe the morbidity of elimination delay in Chinese children with acute lymphoblastic leukemia during high-dose methotrexate (HDMTX) therapy and the toxicities in Children's hospital of Zhejiang University School of Medicine of Chaina between January 2000 and January 2003. e overall morbidity was 12.1% among a total of 497 infusions. Patients with elimination delay had lower platelet count (P<0.01) and greater cumulative CF rescuing intensity (P<0.001).
Another study done by R Jagarlamudi et al published on 2002 included 240 infective episodes in ALL patients showed that clinically documented infections were found in 52% cases with 48% isolated febrile episodes without focus. ey found respiratory system as the most common site (35.7%) of infection. 23 A prospective study done on 1980 by Chessell MJ and Leiper AD which included both ALL and AML patient during their induction therapy showed that the incidence of infection was 40%; only 1% patient died.
e organism responsible for most infections were Pseudomonas aeroginosa and Staphylococcus aureus. E.coli was also responsible for infection in their study. 24 Cwiekliska M et al also found 40%-50% incidence of infection in their study. 25 In another previous study done by Katsimpardi K et al 26 showed that Pseudomonas aeroginosa, Klebsilla pneumonia and E coli were the organisms most commonly isolated. Meir et al 27 found 37% microbiologically documented infection where gram positive cocci followed by gram negative bacilli were isolated in most of the cases.
In UK, a study conducted by Hutchison J H et al 28 to analyze treatment in childhood leukemia with methotrexate included 78 patients receiving CNS prophylaxis and 90 patients not receiving CNS prophylaxis. Study showed that proportion of patients with neutrophil counts below 1x10 9 /l were more in the prophylaxis group and emphasized the correlation between neutropenia and serious pyogenic infection in acute leukemia patient.
In an attempt to nd out the incidence of infection in pediatric Acute Lymphoblastic Leukemia during High dose Methotrexate, this prospective observational study was done in 50 patients. Nineteen (38%) of them developed infection during HDMTX therapy which is comparable to the estimation of 40% reported by Chessells and Alison DL 24 during remission induction period of ALL patient and 40%-50% reported by Cwiekliska M et al. 25 e mean age of study population was 5.78±3.66 years. Study done by Santolaya M et al showed the mean age was 7±4 years. 29 Among the study group 64% cases were male; indicating male preponderance and among them 31[62%] were younger than 5 year; similar to the study done by Jacques N and Judith MC.
In a previous study done by Jagarlamudi R et al showed that clinically documented infections were 52% and 48% was isolated febrile episodes without focus. 23 Our study was di erent from most of the studies where respiratory system was the most common site of infection, whereas in our study, it is the second most common site. 23, 30 Microbiologically documented infections found in 9 occasions with predominance of gram negative bacilli such as E coli (4,44.4%) & Pseudomonas (3, 33.33%). Gram positive organism Staphylococcus aureus also contributed in 2 (22.22%) occasions in this study. is is comparable to Katerina Katsimpardiet al 26 which also showed predominance of gram negative organism (Pseudomonas , K pneumonia and E coli). Chessell MJ and Leiper AD showed that the organism responsible for most infections were Pseudomonas aeroginosa followed by Staphylococcus aureus and E coli 24 , whereas Meir et al 27 found gram positive cocci followed by gram negative bacilli in most of the cases.
In our study we found that 31.58% episodes of infections resolved with the rst line antibiotic combination (ceftipime, amikacin) and 52.63% episodes required modi cation of treatment.S.Mahmood et al 35 reported that, 72% episode resolved with rst line antibiotics and 24% need modi cation.
e main cause of high rate of modi cation of treatment in our centre may be due to rapid growth of bacterial resistance as well as due to co infection with other pathogen.
e mean (±SD) duration of treatment received was 12.05±7 days in our study. More than half of the patient received antibiotics for 7-10 days. Average length of antibiotic therapy was 8.4 days in a study by Mahmood S et al. 31 Rodriguez V et al 32 suggests in their study that it is important in patients apparently responding to antibiotics to continue treatment for a minimum of 7-10 days even if cultures prove sterile; too early cessation of treatment may cause relapse of infection and death.
Here 3 patients died due to infectious complication during study period. Death due to infection occurred in 6% of patients among study population. Jacques N and Judith M C 21 found infection caused the death in 8% of patient which was almost similar to our result. Simone et al 33 in 1972 reported 16% fatality and Craft et el 34 in 1977 found 18% death due to infection. But in the study of Judith M C 21 and Leiper AD 24 only 1 patient (0.5%) died due to infection in 1980. Although mortality rate was decreased than previous years; still infection related death was unacceptably high.
Children younger than 5 years and male patients had a signi cantly higher rate of infection in our study. Jacques N and Judith M C 21 also found higher rate of infection in child below 5 years of age, although they did not found any signi cant di erence of incidence of infection among male and female sex. As immune system is not well developed in this group of patient and upper respiratory tract infections are more severe in younger children 21 , this may be the probable cause of high rate of infections in this age group.
In this study vomiting was the presenting feature in almost all the patient 19(100%), eight (42.10%) patients presented with oral mucositis, abdominal pain in 7(36.84%) patient, diarrhea in 6(31.58%), cough in 5(26.31%) patients. Other features include hematemesis-melena 4(21.05%), swollen cannula site 3(15.78%), respiratory distress 3(15.78%), skin lesion in 3(15.78%), convulsion in 2(10.52%) and 1(5.26%) patient presented with headache. ese clinical features are almost similar to the study done by Charlotte R et al. 35 Mucositis was the most common GIT side e ect according to them. Cheng KK 36 also found oral mucositis as a major toxicity associated with HD-MTX.
In our study we found only 16 out of 50 patient had WBC count below 4000/mm 3 . Charlotte R et al 35 Near about half of the patients with infection showed mild to severe thrombocytopenia.
e study also showed very severe neutropenia (0-100 mm 3 /) in 21.1%, severe neutropenia (100-500/mm 3 ) in 10.5%, moderate neutropenia (500-1000/mm 3 ) in 5.3% and no neutropenia (>1000/mm 3 ) in 63.2% infectious episodes. Meir HM et al 27 found 31%, 44% and 25% episodes were associated with ANC <100/mm 3 , ANC <500/mm 3 , ANC >500/mm 3 respectively .
Comparison to our results with those published by other centers in the world has shown many similar and few di erent ndings. From the current study we should stress the importance of frequency, severity and outcome of infections in such critically ill patients over the years in order to detect changing epidemiologic patterns.
Incidence of infections during HDMTX therapy is high. Mortality rate was also unacceptably high as per this study. Children younger than 5 years and male child are more prone to infection. Gram negative organism (E coli, Pseudomonus) were the main pathogen and GIT was the commonest site of infection according to this study.
is was a single centre study and there were some other limitations as well. So in future, study with large sample size and long study period should be done and the supportive care management of ALL during HDMTX therapy should be improved.
